Josep Tabernero, MD, PhD

How to Make MSS Tumors More Sensitive for Immunotherapy?

07/07/2023

KRYSTAL-10: A randomized phase 3 study of adagrasib (MRTX849) in combination with cetuximab vs chemotherapy in patients with previously treated advanced colorectal cancer with KRASG12C mutation

Background KRAS G12C mutation occurs in 3-4% of colorectal cancer (CRC) and is associated with poor prognosis. KRAS is a key mediator of the RAS/MAPK signaling cascade a...

Josep Tabernero , MD, PhD;

06/28/2021

Videos

Sequencing of Encorafenib Plus Cetuximab Among Patients With BRAF-Mutant Metastatic Colorectal Cancer

08/25/2023

Josep Tabernero , MD, PhD;

At the 2023 World Congress on Gastrointestinal Cancers, Josep Tabernero, MD, PhD presented a post hoc analysis of the BEACON trial that evaluated differences among patients with BRAF V600E-mutant metastatic colorectal cancer treated with...

At the 2023 World Congress on...

08/25/2023

Oncology

PERSPECTIVE: Tepotinib plus cetuximab in patients with RAS/BRAF wild-type left-sided metastatic colorectal cancer and acquired resistance to anti-EGFR antibody therapy due to MET amplification

Background MET amplification (METamp) is a secondary, or co-driving, genetic change in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-...

Josep Tabernero , MD, PhD;

06/28/2021

A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy compared with chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015

Background Combination chemotherapy with fluoropyrimidine and platinum is recommended by the National Comprehensive Cancer Network as a first-line treatment option for p...

Eric Van Cutsem , MD, PhD;

Josep Tabernero , MD, PhD;

06/28/2021

MONEO: A phase II study of avelumab plus FLOT in the peri-operative treatment for patients with resectable gastric or gastroesophageal junction cancer

Background Gastric or gastroesophageal junction cancer (GC) represents a worldwide problem; radical surgery remaining the gold standard of curative treatment. In the Wes...

C. De Andrea ;

P. Jimenez-Fonseca ;

V. Arrazubi ;

M. Diez Garcia ;

E. Sanz-Garcia ;

E. Martinez de Castro ;

R. Guardeno Sanchez ;

M. Calvo Campos ;

C. Buges Sanchez ;

A. Gros ;

A. Vivancos ;

Josep Tabernero , MD, PhD;

M. Alsina ;

S. Munoz ;

M. Ponz-Sarvise ;

I. Melero ;

D. Lopez Garcia ;

M. Gonzalez ;

G. Villacampa ;

F. Munoz ;

06/28/2021

Emerging Concepts in HER2-Driven Gastrointestinal Cancers

Kohei Shitara , MD;

Josep Tabernero , MD, PhD;

Salvatore Siena , MD;

Eric Van Cutsem , MD, PhD;

08/16/2019

HERIZON-GEA-01: A phase 3 study of zanidatamab in combination with chemotherapy with or without tislelizumab in first-line human epidermal growth factor receptor 2 positive (HER2+) advanced/metastatic gastroesophageal adenocarcinoma (GEA)

Background Gastroesophageal adenocarcinomas (GEAs), including gastric, esophageal, and gastroesophageal junction (GEJ) adenocarcinomas, are common cancers with high morb...

Josep Tabernero , MD, PhD;

06/27/2022

O-002: Ibrutinib in Combination With Nab-Paclitaxel and Gemcitabine as First-Line Treatment for Patients With Metastatic Pancreatic Adenocarcinoma: Results From the Phase 3 RESOLVE Study

Access the abstract

Jean-Baptiste Bachet ;

Heung-Moon Chang ;

Joan Maurel ;

Lisa M. Coussens ;

Lawrence Fong ;

L. Claire Tsao ;

George Cole Jr.;

Danelle James ;

Michele Reni ;

Do-Youn Oh ;

Eric Van Cutsem , MD, PhD;

Margaret A. Tempero , MD;

Teresa Macarulla , MD, PhD;

Josep Tabernero , MD, PhD;

Andrew Hendifar ;

Naureen Starling , MBBS, MD;

Dirk-Thomas Waldschmidt ;

Sara Lonardi ;

07/31/2019

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in progress

Background Tucatinib (TUC), a highly selective HER2-directed tyrosine kinase inhibitor (TKI) approved in multiple regions for HER2+ metastatic breast cancer, is being de...

Josep Tabernero , MD, PhD;

06/27/2022